China implants first commercial brain chip, outpacing US rivals
Surgeons in Shanghai have implanted the world’s first commercially approved brain-computer interface, signalling a state-backed industrial approach that could outpace Western neurotech rivals in getting medical devices to patients.
Surgeons at Huashan Hospital in Shanghai have successfully implanted a coin-sized brain-computer interface in a patient who lost hand function to a spinal-cord injury a decade ago. The device, called NEO and developed by Neuracle Medical Technology, captured stable brain signals during the procedure. The patient is reportedly recovering with steady vital signs.
What distinguishes this milestone is the regulatory and commercial status of the device. NEO received approval from China’s National Medical Products Administration in March, making it a prescribable product rather than an experimental research tool. Within four months, the implant moved through manufacturing, hospital rollouts, patient screening, and integration into local commercial health insurance.
For European medtech investors and regulators, this speed of productisation is the metric that matters. While the US leads in ambitious, high-fidelity implants like Neuralink—which threads electrodes directly into brain tissue—those devices remain tied up in trials without full commercial clearance from the FDA. China has instead opted for a lower-risk, surface-level device that is easier to regulate and insure, prioritising immediate market availability over maximum technical capability.
This rapid deployment is the result of a coordinated industrial push. Beijing has designated brain-computer interfaces as a strategic future industry, with a blueprint demanding breakthroughs by 2027 and the cultivation of two or three global leaders by 2030. Neuracle is already preparing for a Shanghai stock listing, supported by a system that aligns regulatory approval, manufacturing, and insurance coverage under a single national strategy.
The trade-off for this speed is capability. Because NEO rests on the brain's protective membrane with just eight electrodes, it captures less neural detail than invasive American alternatives. It aims to restore a limited slice of hand function, falling short of the sweeping computer and robotic control promised by more ambitious rivals.
However, as the field matures, questions about neural-data privacy and the boundaries of consumer neurotech will soon force regulators globally to react. China is already pursuing non-invasive wearable headsets for the mass market alongside these surgical implants. For European policymakers watching this space, the immediate takeaway is that the global race is no longer just about who builds the most powerful brain chip, but who can navigate regulation and insurance to actually put one in a patient.
